Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: A multicenter trial

International Journal of Gynecological Cancer

Volumn 16, Issue 1, 2006, Pages 52-56

  Utsunomiya, H ^a   Akahira, J ^a   Tanno, S ^a   Moriya, T ^a   Toyoshima, M ^a   Niikura, H ^a   Ito, K ^a   Morimura, Y ^b   Watanabe, Y ^c   Yaegashi, N ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Department of Obstetrics and Gynecology   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Clear cell adenocarcinoma; Ovary; Paclitaxel; Platinum

Indexed keywords

PACLITAXEL; PLATINUM;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER GRADING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MEDICAL RECORD; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33645372538     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00289.x     Document Type: Review

References (28)

1. Akahira J Yoshikawa H Shimizu Y et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001 81 398 403.
2. Del Campo JM Felip E Rubio D et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol 1994 53 27 32.
3. Omura GA Brady MF Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991 9 1138 50.
4. Fanning J Bennett TZ Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992 80 954 60.
5. McGuire WP Hoskins WJ Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334 1 6.
6. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003 361 2099 106.
7. Dizon DS Hensley ML Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002 20 1238 47.
8. Rose PG Fusco N Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998 16 1494 7.
9. Serov SF Scully RE Sobin LH. International histologic classification of tumors. No. 9. Histologic typing of ovarian tumors. Geneva, Switzerland World Health Organization 1973.
10. Aure JC Hoeg K Kolstad P Mesonephroid tumors of the ovary: clinical and histopathologic studies. Obstet Gynecol 1971 37 860 7.
11. Kennedy AW Biscotti CV Hart WR Webster KD. Ovarian clear cell adenocarcinoma. Gynecol Oncol 1989 32 342 9.
12. Crozier MA Copeland LJ Silva EG et al. Clear cell carcinoma of the ovary: a study of 59 cases. Gynecol Oncol 1989 35 199 203.
13. O'Brien ME Schofield JB Tan S et al. Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 1993 49 250 4.
14. Sugawa T Umesaki N Yajima A et al. A group study on prognosis of ovarian cancer. Acta Obstet Gynaecol Jpn 1992 44 827 32.
15. Ueki M. Report of gynecologic cancer in Japan. Acta Obstet Gynaecol Jpn 2001 53 1038 48.
16. Shimizu Y Umezawa A Hasumi K. A phase II study of combined CPT-11 and mitomycin C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore 1998 27 650 6.
17. Sugiyama T Kamura T Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000 88 2584 9.
18. Recio FO Piver MS Hempling RE Driscoll DL. Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 1996 78 2157 63.
19. Goff BA Sainz dela Cuesta R Muntz HG et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996 60 412 7.
20. Behbakht K Randall TC Benjamin I et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol 1998 70 255 8.
21. Jenison EL Montag AG Griffiths CT et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol 1989 32 65 71.
22. Ho CM Chien TY Shih BY Huang SH. Evaluation of complete surgical staging with pelvic and para-aortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003 88 394 9.
23. Therasse P Arbuck SG Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000 92 205 16.
24. Enomoto T Kuragaki C Yamasaki M et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc ASCO 2003 20 447.
25. Guastalla JP Pujade-Lauraine E Weber B et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 1998 9 37 43.
26. Ohta I Gorai I Miyamoto Y et al. Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells. Cancer Lett 2001 162 39 48.
27. Cloven NG Kyshtoobayeva A Burger RA Yu IR Fruehauf JP. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004 92 160 6.
28. Itamochi H Kigawa J Sultana H et al. Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002 93 723 8.